Molina-Jaimes A, Olmedo-Reneaum A, Martínez-Toledo ÁA, González-Ayala M, Molina M, Sanabria-Trujillo G

Language: Spanish
References: 27
Page: 170-176
PDF size: 197.01 Kb.

ABSTRACT

Background. Carbapenem-resistant gram-negative bacilli can cause life-threatening infections, and treatment options are limited. Ceftazidime-avibactam has been shown to be an effective treatment against these microorganisms.
Objective. To report the clinical, biochemical, and microbiological outcomes of ceftazidime-avibactam against carbapenem-resistant gram-negative bacilli infections (specifically Enterobacterales and Pseudomonas aeruginosa) in patients at two hospitals in Mexico.
Methods. This was an observational, retrospective study at two hospitals in Mexico City. All patients with carbapenem-resistant gram-negative bacilli infections who received ceftazidime-avibactam as definitive antimicrobial therapy were included. Microorganism identification and susceptibility were determined using the Vitek2 system, using CLSI 2019 breakpoints. The main clinical outcomes were clinical and microbiological cure.
Results. Seventy-nine cases of carbapenem-resistant gram-negative bacilli infections were analyzed. Infectious syndromes included: 40% urinary tract infection, 18% healthcare-associated pneumonia, 17% central venous catheter-associated bacilli, 15% postsurgical infections, and 9% complicated skin and soft tissue infections. Clinical cure was achieved in all cases of bacilli, healthcare-associated pneumonia, and skin and soft tissue infections, and in 87.5% of urinary tract infections. Microbiological cure was recorded in all cases of bacilli, 92% of urinary tract infections, and 72.7% of healthcare-associated pneumonia.
Conclusions. These results support ceftazidime-avibactam treatment for infections caused by carbapenem-resistant gram-negative bacilli. However, in our country, studies involving a larger population are needed to generalize these results.

REFERENCES

1. Centers for Disease Control and Prevention (cdc), “Antibioticresistance threats in the United States, 2019”,Atlanta, GA, U.S. Department of Health and HumanServices, cdc, 2019. (Consultado el 5 de diciembre de 2021.)

2. Nelson, R.E., Hatfield, K.M., Wolford, H., Samore, M.H.,Scott, R.D., Reddy, S.C. et al., “National estimates ofhealthcare costs associated with multidrug-resistantbacterial infections among hospitalized patients inthe United States”, Clin Infect Dis, 2021, 72 (Suppl 1):s17-s26.

3. García-Betancur, J.C., Appel, T.M., Esparza, G., Gales,A.C., Levy-Hara, G., Cornistein, W. et al., “Update on theepidemiology of carbapenemases in Latin America andthe Caribbean”, Expert Rev Anti Infect Ther, 2021, 19 (2):197-213.

4. 4, Garza-González, E., Franco-Cendejas, R., Morfín-Otero,R., Echaniz-Avilés, G., Rojas-Larios, F., Bocanegra-Ibarias,P. et al., “The evolurinary tract infections on of antimicrobialresistance in Mexico during the last decade:results from the invifar Group”, Microb Drug Resist,2020, 26 (11): 1372-1382.

5. Das, S., Li, J., Riccobene, T., Carrothers, T.J., Newell,P., Melnick, D. et al., “Dose selection and validationfor ceftazidime-avibactam in adults with complicatedintra-abdominal infections, complicated urinary tractinfections, and nosocomial pneumonia”, AntimicrobAgents Chemother, 2019, 63 (4): e02187-18.

6. Alraddadi, B.M., Saeedi, M., Qutub, M., Alshukairi, A.,Hassanien, A. y Wali, G., “Efficacy of ceftazidime-avibactamin the treatment of infections due to carbapenem-resistant Enterobacteriaceae”, bmc Infect Dis,2019, 19 (1): 772.

7. Shields, R.K., Nguyen, M.H., Chen, L., Press, E.G,. Potoski,B.A., Marini, R.V. et al., “Ceftazidime-avibactamis superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia”,Antimicrob Agents Chemother, 2017, 61 (8): e00883-17.

8. Tuon, F.F., Aragao, B.Z., Santos, T.A., Gasparetto, J., Córdova,K. y Abujamra, M., “Acute kidney injury in patientsusing amikacin in an era of carbapenem-resistant bacteria”,Infect Dis (Londres), 2016, 48 (11-12): 869-871.

9. Sanches Ito C.A., Bail, L., Villa Stangler Arend, L.N., SilvaNogueira, K.D. y Tuon, F.F., “The activity of ceftazidime/avibactam against carbapenem-resistant Pseudomonasaeruginosa”, Infect Dis (Londres), 2021, 53 (5): 386-389.

10. Trecarichi, E.M. y Tumbarello, M., “Therapeurinary tractinfections options for carbapenem-resistant Enterobacteriaceaeinfections”, Virulence, 2017, 8 (4): 470-484.

11. Tsolaki, V., Mantzarlis, K., Mpakalis, A., Malli, E., Tsimpoukas,F., Tsirogianni, A. et al., “Ceftazidime-avibactamto treat life-threatening infections by carbapenem-resistantpathogens in critically ill mechanically ventilatedpatients”, Antimicrob Agents Chemother, 2020, 64 (3):e02320-19

12. Weinstein, M.P. y Lewis, J.S., “The Clinical and LaboratoryStandards Institute Subcommittee on AntimicrobialSusceptibility Testing: background, organization,functions, and processes”, J Clin Microbiol, 2020, 58:e01864-19.

13. Torres, A., Niederman, M.S., Chastre, J., Ewig, S., Fernández-Vandellos, P., Hanberger, H. et al., “Internationalers/esicm/escmid/alat guidelines for the management ofhospital-acquired pneumonia and ventilator-associatedpneumonia: guidelines for the management of hospital-acquired pneumonia (hap)/ventilator-associatedpneumonia (vap) of the European Respiratory Society(ers), European Society of Intensive Care Medicine(esicm), European Society of Clinical Microbiology andInfectious Diseases (escmid) and Asociación Latinoamericanadel Tórax (alat)”, Eur Respir J, 2017, 50 (3):1700582.

14. Horan, T.C., Andrus, M. y Dudeck, M.A., “cdc/nhsn surveillancedefinition of health care-associated infectionand criteria for specific types of infections in the acutecare setting”, Am J Infect Control, 2008, 36 (5): 309-332.

15. Humphries, R., Campeau, S., Davis, T.E., Nagaro, K.J., La-Bombardi, V.J., Franklin, S. et al., “Multicenter evaluationof ceftazidime-avibactam susceptibility testing of Enterobacteralesand Pseudomonas aeruginosa on the Vitek 2System”, J Clin Microbiol, 2021, 59 (3): e01870-20.

16. Sader, H.S., Castanheira, M., Shortridge, D., Mendes,R.E. y Flamm, R.K., “Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceaeand Pseudomonas aeruginosa isolatesfrom U.S. medical centers, 2013 to 2016”, AntimicrobAgents Chemother, 2017, 61 (11): e01045.

17. Stone, G.G., Newell, P., Gasink, L.B., Broadhurst, H.,Wardman, A., Yates, K. et al., “Clinical activity of ceftazidime/avibactam against mdr Enterobacteriaceae andPseudomonas aeruginosa: pooled data from the ceftazidime/avibactam phase iii clinical trial programme”, JAntimicrob Chemother, 2018, 73 (9): 2519-2523.

18. Torres, A., Rank, D., Melnick, D., Rekeda, L., Chen,X., Riccobene, T. et al., “Randomized trial of ceftazidime-avibactam vs meropenem for treatment ofhospital-acquired and ventilator-associated bacterialpneumonia (reprove): analyses per US fda-specified endpoints”, Open Forum Infect Dis, 2019, 6 (4): ofz149.

19. Mazuski, J.E., Wagenlehner, F., Torres, A., Carmeli, Y.,Chow, J.W., Wajsbrot, D. et al., “Clinical and microbiologicaloutcomes of ceftazidime-avibactam treatment inadults with gram-negative bacteremia: a subset analysisfrom the phase 3 clinical trial program”, Infect DisTher, 2021, 10 (4): 2399-2414.

20. Livermore, D.M., Meunier, D., Hopkins, K.L., Doumith,M., Hill, R., Pike, R. et al., “Activity of ceftazidime/avibactamagainst problem Enterobacteriaceae and Pseudomonasaeruginosa in the UK, 2015-16”, J AntimicrobChemother, 2018, 73 (3): 648-657.

21. Liao, C.H., Lee, N.Y., Tang, H.J., Lee, S.S., Lin, C.F., Lu,P.L. et al., “Antimicrobial activities of ceftazidime-avibactam,ceftolozane-tazobactam, and other agents againstEscherichia coli, Klebsiella pneumoniae, and Pseudomonasaeruginosa isolated from intensive care unitsin Taiwan: results from the surveillance of multicenterantimicrobial resistance in Taiwan in 2016”, Infect DrugResist, 2019, 12: 545-552.

22. Molina, A., Salinas-Hernández, A. y Olmedo-Reneaum,A., “1290. Ceftazidime-avibactam resistance report in athird level hospital in Mexico City”, Open Forum InfectDis, 2021, 8 (Suppl 1): s734.

23. Appel, T.M., Mojica, M.F., De la Cadena, E., Pallares,C.J., Radice, M.A., Castañeda-Méndez, P. et al., “In vitrosusceptibility to ceftazidime/avibactam and comparatorsin clinical isolates of Enterobacterales from fiveLatin American countries”, Antibiotics (Basilea), 2020, 9(2): 62.

24. Jorgensen, S.C.J., Trinh, T.D., Zasowski, E.J., Lagnf,A.M., Bhatia, S., Melvin, S.M. et al., “Real-world experiencewith ceftazidime-avibactam for multidrug-resistantgram-negative bacterial infections”, Open ForumInfect Dis, 2019, 6 (12): ofz522.

25. Onorato, L., Di Caprio, G., Signoriello, S. y Coppola,N., “Efficacy of ceftazidime/avibactam in monotherapyor combination therapy against carbapenem-resistantgram-negative bacteria: a meta-analysis”, Int J AntimicrobAgents, 2019, 54 (6): 735-740.

26. Temkin, E., Torre-Cisneros, J., Beovic, B., Benito, N.,Giannella, M., Gilarranz, R. et al., “Ceftazidime-avibactamas salvage therapy for infections caused bycarbapenem-resistant organisms”, Antimicrob AgentsChemother, 2017, 61 (2): e01964-16.

27. Zhang, Y., Tao, L.N., Qu, X.Y., Niu, J.Q., Ding, Y.H. yZhang, S.X., “Efficacy and safety of ceftazidime-avibactamin the treatment of complicated intra-abdominalinfections (ciais) and complicated urinary tract infections(curinary tract infectionss): a meta-analysis of randomizedcontrolled trials”, Revista da Associação MédicaBrasileira, 2018, 64: 253-263.